Breaking Finance News

Zacks Investment Research downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) to Hold in a statement released today.

Zacks Investment Research has downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) to Hold in a statement released on 11/26/2016.

On 11/25/2016, Zacks Investment Research released a statement for PTC Therapeutics, Inc. (NASDAQ:PTCT) bumped up the target price from $0.00 to $14.00 that suggested an upside of 0.14%.

Showing a price of $12.41, PTC Therapeutics, Inc. (NASDAQ:PTCT) traded 0.81% higher on the day. With the last close up 48.94% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. PTC Therapeutics, Inc. has recorded a 50-day average of $9.17 and a two hundred day average of $8.33. Volume of trade was down over the average, with 389,908 shares of PTCT changing hands under the typical 2,189,140

Performance Chart

PTC Therapeutics, Inc. (NASDAQ:PTCT)

With a total market value of $0, PTC Therapeutics, Inc. has with a one year low of $4.03 and a one year high of $35.40 .

More About PTC Therapeutics, Inc. (NASDAQ:PTCT)

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.